Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia this week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA – Shaffiq Essajee spoke during today’s plenary session about HIV prevention and treatment for children with a strong focus on the treatment side. “While we are seeing 60 […]
Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia this week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA – Professor David Cooper kicked off the final opening plenary in Melbourne today with a review on antiretroviral therapy including a look at recommended drug regimens for first- […]
Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia through the week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA – Activists surprised Gilead corporate executives today with a “die-in” to protest the pricing of Gilead’s hepatitis C drug, Solvaldi (sofosbuvir). As Gregg Alton, Gilead’s Executive Vice-President […]
Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia through the week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA – Laurindo Garcia, a gay man living with HIV in the Philippines offered a moving conclusion to the opening plenary In Melbourne on Thursday, speaking to […]
Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia through the week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA – During the opening plenary today, Beatriz Grinszteijn offered insights about men with have sex with men and transgender women echoing many of the themes raised in […]
HIV
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
Tuberculosis
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
With a report showing that 2018 yielded the highest case numbers seen so far of a paralyzing condition largely among children who had been sick with […]